Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 12Terminated 3Recruiting 3Withdrawn 1Unknown 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Plasma cell 1Classical hematology 1CNS 1

Conditions

Lymphoma, Large B-Cell, Diffuse 41Lymphoma, B-Cell, Marginal Zone 22Lymphoma, Mantle-Cell 20Lymphoma, Follicular 18Lymphoma 17Lymphoma, Non-Hodgkin 15Leukemia, Lymphocytic, Chronic, B-Cell 12Lymphoma, B-Cell 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Recurrence 8Burkitt Lymphoma 8Waldenstrom Macroglobulinemia 7Neoplasms 6Leukemia, Hairy Cell 4Leukemia, B-Cell 3Leukemia 3Hematologic Neoplasms 3beta-Thalassemia 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm, Residual 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Heart Failure 2Epstein-Barr Virus Infections 2Dendritic Cell Sarcoma, Interdigitating 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Anemia, Refractory, with Excess of Blasts 2Thalassemia 1Sjogren's Syndrome 1

Interventions

Cyclophosphamide 22fludarabine 20venetoclax 8Whole-Body Irradiation 8Mycophenolic Acid 8Standard of Care 6Mesna 6Melphalan 6Azacitidine 6fludarabine phosphate 5Sirolimus 5thymoglobulin 4Thiotepa 4Tacrolimus 4Surveys and Questionnaires 4Specimen Handling 4Filgrastim 4Cytarabine 4entrectinib 3daratumumab 3cobimetinib 3alectinib 3Vemurafenib 3Rituximab 3Practice Guidelines as Topic 3Palliative Care 3Granulocyte Colony-Stimulating Factor 3Busulfan 3Bortezomib 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Hematologic Neoplasms × Rituximab × Clear all
NCT04844866 2026-04-29

DALY 2-EU

Miltenyi Biomedicine GmbH

Phase 2 Recruiting
213 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

NCT05735717 2026-04-06

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Masonic Cancer Center, University of Minnesota

Phase 2 Recruiting
70 enrolled
CNSClassical hematologyLymphoidOther hematologic neoplasm

Chromosome 7, monosomy, Anemia, Refractory, with Excess of Blasts, Chromosome Aberrations, Influenza, Human, Neurofibromatosis 1, Leukemia, Myeloid, Acute, beta-Thalassemia, Neoplasm, Residual, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT06119685 2025-06-03

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Indapta Therapeutics, INC.

Phase 1/2 Recruiting
128 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡